The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
about
The epigenetic landscape of acute myeloid leukemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaPrevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasmsRecurring mutations found by sequencing an acute myeloid leukemia genomeIdentification of AML1-ETO modulators by chemical genomicsUse of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studyAcute myeloid leukemia in the older adultsDefining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesVolasertib for AML: clinical use and patient considerationCore Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesSirtuins in hematological aging and malignancyHox expression in AML identifies a distinct subset of patients with intermediate cytogeneticsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewEarly prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survivalA single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialA phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesGlobal Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsGenetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemiaSalvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDEffect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaEffect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Challenges in treating older patients with acute myeloid leukemia.Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group.Adult Acute Myeloid Leukemia Long-term Survivors.The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).
P2860
Q21284742-DF764C95-927B-4E64-A80C-10437070E749Q24186270-3662EB45-CEBB-4CBB-BCFA-035AF3933D04Q24186284-34437A55-5709-4C7F-BA43-2017B4A8B0C0Q24234645-EA0C8CA6-7D9B-4342-B904-AF0ACC0549FBQ24234680-53C6AFE1-46AA-4C3D-A3E9-F35DD9FB040EQ24595117-7D37BE0F-8BF5-4E75-8236-76D54B5354E4Q24634204-3D95D32F-6D3B-4346-933C-D216951582C5Q24643359-2861404F-01AB-4DD7-9C0F-DCB2D1BEA985Q24670020-7C9C5564-EA64-4D5B-B6C4-0DB4CFCE9CBBQ26740584-D2AC3B8C-C563-4D88-A9C3-45CCEC57739EQ26772235-B154580C-667A-4D02-94DB-79A72A998686Q26801131-DF5EC0D3-1A3D-4629-BA98-1360E6EB3439Q26863756-8A3AF46D-5679-4597-B282-E2F369879DE6Q26991467-9E63C64F-BC20-4171-9F28-B225CD62FAB7Q28256635-AA26E267-EFE1-49F7-BD08-41A88A9272A6Q28301344-CE00549B-B208-4421-9E74-AE137860339FQ33245160-D78A2EE8-F80C-44F2-B30E-DD4D0FC09165Q33264716-EE466F84-35A0-4C59-9C1E-8E1F98E763D0Q33318747-F58619B1-FACE-435C-8DA9-E7B29F824DBAQ33350688-4F80160F-7744-4F76-ABC1-EA75576A011EQ33392683-E55A7CF1-079B-4FDD-9651-63C972E46FD8Q33431584-AD70BF51-6EAD-45A3-BFDA-4BFF35788E24Q33518976-7D70F677-ABA4-4DBA-BBD2-357DEA3ADF42Q33555287-B2B81842-820E-4168-AE25-F5DA7A9DFFD0Q33555627-6765FB13-EB04-42D7-A21A-E5CD6360BE39Q33556931-3F41A1BD-246B-4CE1-BD23-419657919492Q33558780-FD65E62E-9581-43F6-A2C8-6B9E75264B62Q33574178-214E07F6-16C9-4787-B982-A07425DFE047Q33598706-A045D350-4B90-4B56-B640-7E58003512B3Q33798909-EC7F106D-DC99-4BF8-9092-3D28D438FD72Q33813439-D99D65C7-5B59-4D20-B1EB-472575E1EE3DQ33841129-6976F476-7EA1-4562-B1DB-98BC37155D3EQ33914289-B5F26FDD-A342-4181-8EB3-8CAA4A40C91EQ33943277-C5524ED9-0591-47B7-89C5-1D81E4427442Q33968372-439D5D80-F317-4196-A3CE-010673372B77Q33985549-78F329F9-E003-4465-B60B-D2DF3693805FQ34011740-737AF4F4-8115-43B2-B604-867556B93A84Q34038587-63F3F8FF-7C89-41A4-8BE0-5B5A9D75444BQ34202366-A4837ADD-A2EC-4B29-99D9-AF344CE3A629Q34276134-660FFC52-65AA-4FF0-95A3-5E266AB13722
P2860
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
The predictive value of hierar ...... Research Council AML11 trial.
@ast
The predictive value of hierar ...... Research Council AML11 trial.
@en
The predictive value of hierar ...... ts with acute myeloid leukemia
@nl
type
label
The predictive value of hierar ...... Research Council AML11 trial.
@ast
The predictive value of hierar ...... Research Council AML11 trial.
@en
The predictive value of hierar ...... ts with acute myeloid leukemia
@nl
prefLabel
The predictive value of hierar ...... Research Council AML11 trial.
@ast
The predictive value of hierar ...... Research Council AML11 trial.
@en
The predictive value of hierar ...... ts with acute myeloid leukemia
@nl
P2093
P356
P1433
P1476
The predictive value of hierar ...... Research Council AML11 trial.
@en
P2093
A H Goldstone
A K Burnett
C J Harrison
D Grimwade
G Harrison
K Wheatley
Medical Research Council Adult Leukemia Working Party
S Chatters
P304
P356
10.1182/BLOOD.V98.5.1312
P407
P577
2001-09-01T00:00:00Z